Short interest for NextTrip gives investors a sense of the degree to which investors are betting on the decline of NextTrip's stock. Short interest data is updated every two weeks.

NextTrip Stock (NASDAQ:NTRP), Short Interest Report

NextTrip

Sigma Additive Solutions

NextTrip Inc is a technology-driven platform delivering travel booking and travel media solutions. It provides individual and group travelers with vacations to the popular and sought-after destinations in Mexico, the Caribbean and across the world. NextTrip Media platform - Travel Magazine offers a social media platform for viewers to explore, educate and share with friends their "bucket list" travel. Also it is launching an end-to-end content ecosystem that uses AI assisted travel planning capturing advertising, building brand awareness, rewarding loyalty and driving bookings.

Penny Stocks

ABBV

ALEC

BIIB

INMB

NTRP

By Anita Dushyanth, PhD

NASDAQ:INMB | NASDAQ:NTRP | TSX:PMN.TO

Rethinking the approach to treat Alzheimer&#39;s disease

Neurotez: Can Leptin Prove Beneficial for Alzheimer&#39;s Patients?

After-Hours Center

Markets

Movers

Trading Ideas

ADMP

ADVM

AHPI

ALLK

AMAG

AMPH

ARAY

AVCO

AVEO

AVGR

BHVN

CAPR

CBLI

CERS

CFRX

CHFS

CNAT

COCP

COLL

CTSO

CTXR

GHSI

HEPA

HTBX

MGEN

MRNS

NVIV

OCGN

OPGN

OTLK

SGMO

SNSS

TRVN

VKTX

VXRT

43 Healthcare Stocks Moving In Tuesday&#39;s After-Market Session

Education

General

ICCC

TWMC

Why I Love Trading A Small Account, And Why You Should Too

NextTrip Inc

Oppenheimer analyst Hartaj Singh maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Outperform and raises the price target from $142 to $163.

News

Price Target

Analyst Ratings

MRNA

Oppenheimer Maintains Outperform on Moderna, Raises Price Target to $163

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Outperform and lowers the price target from $53 to $52.

KYMR

Oppenheimer Maintains Outperform on Kymera Therapeutics, Lowers Price Target to $52

Rosenblatt analyst Steve Frankel maintains Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) with a Neutral and maintains $15 price target.

UEIC

Rosenblatt Maintains Neutral on Universal Electronics, Maintains $15 Price Target

Biotech

Curiox Biosystems And Beckman Coulter Life Sciences Announces Partnership Combining C-FREE Technology With DURA Innovations For Hands-Free Washed Sample Preparation For Flow Cytometry

Oppenheimer analyst Noah Kaye maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Outperform and raises the price target from $100 to $110.

ITRI

Oppenheimer Maintains Outperform on Itron, Raises Price Target to $110

Oppenheimer analyst Michael Phillips maintains Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Outperform and raises the price target from $150 to $165.

Oppenheimer Maintains Outperform on Hanover Insurance Gr, Raises Price Target to $165

Rosenblatt analyst Steve Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $98 price target.

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $98 Price Target

Guidance

Tennant Reaffirmed FY24 Net Sales Of $1.27B-$1.295B (Est $1.288B), Adjusted EPS Of $6.05-$6.65 (Est $6.46)

Oppenheimer analyst Jed Kelly maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Outperform and lowers the price target from $175 to $155.

EXPE

Oppenheimer Maintains Outperform on Expedia Group, Lowers Price Target to $155

Wedbush analyst Jay McCanless reiterates Redwood Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWT#NYSE">RWT</a>) with a Neutral and maintains $6.5 price target.

Reiteration

Wedbush Reiterates Neutral on Redwood Trust, Maintains $6.5 Price Target

Oppenheimer analyst Kristen Owen maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $67 to $69.

CTVA

Oppenheimer Maintains Outperform on Corteva, Raises Price Target to $69

Management

RIVN

Rivian Hires Javier Varela As COO

CSSE

Chicken Soup For The Soul Entertainment Says Could Be Forced To Seek Protections Under U.S. Bankruptcy Law

Tennant Reaffirmed FY24 Organic Net Sales Growth Of 2.0%-4.0%

Oppenheimer analyst Owen Lau maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Outperform and raises the price target from $276 to $282.

COIN

Oppenheimer Maintains Outperform on Coinbase Glb, Raises Price Target to $282

Rosenblatt analyst Andrew Bond maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Buy and maintains $164 price target.

Rosenblatt Maintains Buy on Intercontinental Exchange, Maintains $164 Price Target

GIGM

GigaMedia CEO James Huang Says We Believe That Will Lead To A Healthier Gross Margin In The Long-run For Our Own Offerings

Oppenheimer analyst Shaul Eyal maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Outperform and lowers the price target from $122 to $110.

Oppenheimer Maintains Outperform on Cloudflare, Lowers Price Target to $110

Oppenheimer analyst Michael Wiederhorn maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and raises the price target from $370 to $400.

Oppenheimer Maintains Outperform on Cigna Group, Raises Price Target to $400

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">CONMED</h3>
<ul>
<li>The Trade: CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) Chief Operating Officer Pat Beyer <a href="https://www.benzinga.com/quote/CNMD/analyst-ratings">acquired a total of 3,000 shares</a> at an average price of $68.30. To acquire these shares, it cost around $204,900.</li>
<li>What's Happening: On April 24, Conmed reported better-than-expected first-quarter financial results.</li>
<li>What CONMED Does: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries.</li>
</ul>
<h3 class="wp-block-heading">Skyworks Solutions</h3>
<ul>
<li>The Trade: Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) Director, Chairman, CEO and President Liam Griffin acquired a total of 11,142 shares at an average price of $90.00. To acquire these shares, it cost around $1 million.</li>
<li>What's Happening: On April 30, Skyworks Solutions reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.52 by 1.97%.</li>
<li>What Skyworks Solutions Does: Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Enphase Energy</h3>
<ul>
<li>The Trade: Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) EVP, CFO Mandy Yang <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 4,000 shares</a> at an average price of  $104.24. To acquire these shares, it cost around $416,972.</li>
<li>What's Happening: On April 23, Enphase Energy reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>What Enphase Energy Does: Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/05/38606910/investor-sentiment-increases-ahead-of-jobs-report-dow-jumps-over-300-points">Investor Sentiment Increases Ahead Of Jobs Report, Dow Jumps Over 300 Points</a>

Long Ideas

Insider Trades

Pre-Market Outlook

CNMD

ENPH

SWKS

$1M Bet On Skyworks Solutions? Check Out These 3 Stocks Insiders Are Buying

NextTrip files to sell common stock, warrants

Press Releases

NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NextTrip Stock (NASDAQ:NTRP), Short Interest Report

People Also Watch